Oraliva, Inc is structured around providing noninvasive, painless, reliable, clinically validated Al linked diagnostics for the detection of oral cancer and oral dysplasia: a point of care/near patient testing platform tecnology for a broad range of cancers. The assembled leadership team of OraLiva Inc. comes out of the diagnostics and life sciences industries - collectively and individually having extensive experience in clinical laboratory logistics, artificial intelligence, microfluidics, and manufacturing. With rhe firm's agile platform allowing for rapid expansion to a large menu of tests, in collaboration with the McDevitt Laboratory at NYU, large clinical studies have been completed to define signatures of early disease. OraLiva Incs first application is targeted for Q3 2023 in the area of oral cancer.
